Pharmacokinetics of cetuximab and tumor uptake of 89Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.

Erik Jacobus Van Helden,Catharina Wilhelmina Menke,Eline Boon,Suzanne van Es,Marc C. Huisman,G.A.M.S. van Dongen,Danielle J. Vugts,Derk Jan A. de Groot,Carla M.L. van Herpen,Elisabeth G.E. de Vries,Otto S. Hoekstra,Henk M.W. Verheul

Pharmacokinetics of cetuximab and tumor uptake of 89Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.

2017

Erik Jacobus Van Helden
Catharina Wilhelmina Menke
Eline Boon
Suzanne van Es
Marc C. Huisman
G.A.M.S. van Dongen
Danielle J. Vugts
Derk Jan A. de Groot
Carla M.L. van Herpen
Elisabeth G.E. de Vries
Otto S. Hoekstra
Henk M.W. Verheul

e15117Background: One third of patients with RAS wild-type metastatic colorectal cancer (mCRC) do not benefit from anti-EGFR inhibitors. Thus, predictive biomarkers to identify patients with primar...

Keywords:

Cetuximab
Pathology
Cancer research
Biomarker (medicine)
Colorectal cancer
Medicine
Pharmacokinetics
predictive biomarker
Oncology
in patient
Internal medicine
advanced colorectal cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations